Advair Generic on Market

Discussion in 'AstraZeneca' started by anonymous, Jan 30, 2019 at 9:31 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Generic approved. Tick tock.
     

  2. anonymous

    anonymous Guest

    We'll be fine.

    Nexium-multibillion dollar product w/ several generics in class
    Crestor- multibillion dollar product w/ several generics in class.
    Seroquel XR- over a billion dollar product w/ several generics in class.
    Brilinta- I believe now over a billion w/ generic clopidogrel in class.

    Will we lose a market share? Probably but I trust the brand teams to have that calculated into realistic objectives. If not, it will cause chaos w/ the field.
     
  3. anonymous

    anonymous Guest

    ha!! You just used the words trust and brand ta in the same sentence. Realistic objectives? You obviously must work somewhere else.

    while I’d like to believe that’s the reason it’s taking so long for q1 goals to drop, we all know it’s because they’re cooking them to be unattainable vs what we’ve already produced for the quarter, like always
     
  4. anonymous

    anonymous Guest

    Nexium generic didn’t produce layoffs since Crestor an Seroquel were still around. Crestor generic caused a realignment with loss of jobs. Generic Seroquel caused an entire division to be fired. There’s been a hiring freeze going on 2 yrs now, generic advair is going to cause something.
     
  5. anonymous

    anonymous Guest

    Correct, it will cause changes at GSK!
     
  6. anonymous

    anonymous Guest

    They had their changes. It’s not going to be status quo here once Symbicort market share is eroded.
     
  7. anonymous

    anonymous Guest

    Then who the hell is gonna launch the triple and all of the other products in the resp pipeline???
     
  8. anonymous

    anonymous Guest

    Bevespi sales to the rescue!
     
  9. anonymous

    anonymous Guest

    never fear Ruud is here---and his shiny new title!!
     
  10. anonymous

    anonymous Guest

    CSO’s
     
  11. anonymous

    anonymous Guest

    I think u missed the OP’s intent. They were listing our brands that competed against competition that went generic, not the parent compound.
    And if u look at COE lists from Jan/ Feb to Nov, there are ~100 less on the list hence the hiring freeze. And with the rumor that whatever positions that they deem
    To be filled will be filled w/ CSO’s tells me they already caused “something” due to this pending generic entrant.
     
  12. anonymous

    anonymous Guest

    HaH! That’s funny. You mean the glorified ups sample delivery people?

    Last cso I had was so worthless when a doc asked her how to use one of the inhalers the girl has no clue. Total embarrassment!! But hey I’m sure the company could care less about credibility to save a buck in these trying times right??? Pascal’s $16 million bonus has to come from somewhere
     
  13. anonymous

    anonymous Guest

    How many of us do they need to sell a me too until the triple comes? Trelegy is sucking wind and our triple will too.
     
  14. anonymous

    anonymous Guest

    What a joke!! They've been trying to copy Advair for years and there is nothing imminent. Go home troll. Post a link that says there is a generic soon to be approved.
     
  15. anonymous

    anonymous Guest

    Read the financial news. It was approved yesterday.
     
  16. anonymous

    anonymous Guest

    Who cares about the triple, I am waiting on the quintuple!
     
  17. anonymous

    anonymous Guest

    It’s already here! Take 1 puff of Trelegy and open your mouth wide while you are inhaling & gargle deez nuts.